Pacira BioSciences (FRA:82P) Other Financing: €-7.5 Mil (TTM As of Mar. 2026)


FRA:82P Pacira BioSciences Inc FRA:82P
75 GF Score
Price €22.40
GF Value €25.72
! 8 Warning Signs
View Full Analysis

What is Pacira BioSciences Other Financing?

Pacira BioSciences FRA:82P +2.75% 75 Other Financing is €-7.5 Mil as of Mar. 2026. GuruFocus rates FRA:82P with a GF Score™ of 75/100 and a GF Value™ of €25.72. The stock has 8 warning signs investors should review.

Pacira BioSciences's Other Financing for the three months ended in Mar. 2026 was €-3.8 Mil.

Pacira BioSciences's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €-7.5 Mil.

Pacira BioSciences Other Financing Historical Data

* Premium members only.

The historical data trend for Pacira BioSciences's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacira BioSciences Other Financing Chart

Pacira BioSciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.00 24.70 -2.08 -32.71 -3.84

Pacira BioSciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.17 -3.22 -1.87 1.36 -3.77
FRA:82P
75GF Score
Pacira BioSciences Inc FRA:82P
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacira BioSciences Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €-7.5 Mil mean?
Pacira BioSciences (FRA:82P) has a Other Financing of €-7.5 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Pacira BioSciences and its competitors.
Is Pacira BioSciences' Other Financing too high?
Pacira BioSciences' current Other Financing is €-7.5 Mil. Overall, Pacira BioSciences has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Other Financing compare to ETON and AMPH?
Pacira BioSciences' Other Financing of €-7.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Pacira BioSciences and its competitors. Pacira BioSciences's current Other Financing is €-7.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current Other Financing of €-7.5 Mil. The stock's GF Value™ is €25.72, compared to a current price of €22.40 — trading 12.9% below its estimated fair value. The current Other Financing is €-7.5 Mil. Pacira BioSciences' overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current Other Financing is €-7.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacira BioSciences (FRA:82P) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of €22.40 is trading 12.9% below its estimated GF Value™ of €25.72.

Key valuation signals for FRA:82P:

  • Other Financing: €-7.5 Mil
  • GF Value™: €25.72 vs. price of €22.40 (12.9% below fair value)
  • GF Score™: 75/100 with 8 warning signs

No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacira BioSciences Business Description

Other Exchanges PCRX:USA82P:Germany
Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
75GF Score

Get the complete analysis for FRA:82P

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.40
Price
€25.72
GF Value